Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19182727 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | April 2025 | October 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19182766 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | April 2025 | September 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19075180 | COMPOSITIONS AND METHODS | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19031360 | HERPES ZOSTER mRNA VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF | January 2025 | August 2025 | Allow | 7 | 0 | 0 | No | No |
| 18938932 | GALLID ALPHAHERPESVIRUS 3 (MDV-2), A VIRAL VECTOR AGAINST DIFFERENT AVIAN PATHOGENS: A NEW VACCINATION STRATEGY IN THE POULTRY INDUSTRY | November 2024 | April 2025 | Allow | 5 | 0 | 0 | No | No |
| 18630996 | ENGINEERING AAV | April 2024 | May 2025 | Allow | 13 | 1 | 0 | No | No |
| 18611550 | MODIFIED VIRAL PARTICLES FOR GENE THERAPY | March 2024 | June 2025 | Allow | 15 | 1 | 0 | No | No |
| 18234573 | VARIANT CLASSIFICATION THROUGH HIGH-CONFIDENCE MUTATION DETECTION FROM FLUORESCENCE SIGNALS MEASURED WITH A MULTIPLE MUTATION ASSAY | August 2023 | January 2026 | Allow | 29 | 0 | 0 | No | No |
| 18350263 | Devices and Methods for Detecting Microorganisms Using Recombinant Reproduction-Deficient Indicator Bacteriophage | July 2023 | August 2025 | Allow | 25 | 1 | 0 | No | No |
| 18036631 | INFLUENZA VIRUS ENCODING A TRUNCATED NS1 PROTEIN AND A SARS-COV RECEPTOR BINDING DOMAIN | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18130166 | ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY | April 2023 | August 2025 | Allow | 29 | 2 | 0 | No | No |
| 18029576 | CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS M-SEGMENT NUCLEIC ACID VACCINE AND METHODS OF USE AND PRODUCTION | March 2023 | November 2025 | Allow | 31 | 0 | 0 | No | No |
| 18028613 | IMPROVED DNA VACCINE FOR SARS-COV-2 | March 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18042913 | NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTOR | February 2023 | March 2026 | Allow | 36 | 2 | 0 | No | No |
| 18042637 | COVID-19 VACCINES WITH TOCOPHEROL-CONTAINING SQUALENE EMULSION ADJUVANTS | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18020797 | FUSION PROTEINS COMPRISING SARS-COV-2 NUCLEOCAPSID DOMAINS | February 2023 | September 2025 | Allow | 31 | 0 | 0 | No | No |
| 18005291 | RECOMBINANT POXVIRIDAE VECTOR EXPRESSING CO-STIMULATORY MOLECULES | January 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18013863 | PERSISTENT MEMORY T-CELL RESPONSES TO CANCER AND INFECTIOUS-DISEASE ANTIGENS BY MANIPULATION OF AMINO ACID-CATABOLISM PATHWAYS | December 2022 | November 2025 | Allow | 35 | 1 | 0 | No | No |
| 18011064 | VACCINES, VACCINE PRIMING, AND ANTIGEN DOSE SPARING | December 2022 | March 2026 | Allow | 39 | 1 | 0 | No | No |
| 18010418 | SWINE INFLUENZA A VIRUS VACCINE COMPRISING A NUCLEIC ACID CONSTRUCT HAVING A SPECIFIC ORDER OF GENES | December 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18010294 | MEASLES VIRUS VACCINE EXPRESSING SARS-COV-2 PROTEIN(S) | December 2022 | February 2026 | Allow | 38 | 1 | 0 | No | No |
| 18001576 | ORAL RECOMBINANT YEAST FOR EXPRESSING S PROTEIN OF NOVEL CORONAVIRUS, PREPARATION THEREFOR, AND APPLICATION THEREOF | December 2022 | January 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18009684 | HIV VACCINE COMPOSITIONS, METHODS, AND USES THEREOF | December 2022 | July 2025 | Allow | 32 | 0 | 0 | No | No |
| 17998467 | SPIKE-IN REFERENCE STANDARD FOR USE IN DETECTING SAMPLE TARGET FROM DNA OR RNA ORGANISM | November 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17923283 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTS | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 17997703 | ANTIGEN COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASES | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 18048960 | MODIFIED IMMUNOGENIC PROTEINS | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17918304 | PARTICLES, DNA & RNA | October 2022 | September 2025 | Allow | 35 | 0 | 0 | No | No |
| 17937751 | INFECTIOUS DISEASE ANTIGENS AND VACCINES | October 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17914174 | CORONAVIRUS VACCINE | September 2022 | February 2026 | Allow | 41 | 1 | 0 | No | No |
| 17819204 | NUCLEIC ACID NANOSTRUCTURE PLATFORM FOR PROGRAMMING IMMUNE STIMULATION | August 2022 | January 2026 | Allow | 42 | 2 | 0 | No | No |
| 17771349 | COMPOSITIONS COMPRISING V2 OPT HIV ENVELOPES | April 2022 | July 2025 | Allow | 38 | 0 | 0 | No | No |
| 17753506 | INFLUENZA VIRUS VACCINES AND USES THEREOF | March 2022 | July 2025 | Allow | 40 | 0 | 0 | No | No |
| 17638005 | CROSS-REACTIVE EPITOPE FOR MULTIPLE SCLEROSIS | February 2022 | July 2025 | Allow | 41 | 1 | 0 | No | No |
| 17627861 | METHOD FOR PRODUCING A MODIFIED BACTERIOPHAGE WITHOUT GENOME MODIFICATION | January 2022 | February 2026 | Allow | 49 | 1 | 0 | No | No |
| 17626879 | SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF | January 2022 | October 2025 | Allow | 45 | 1 | 0 | No | No |
| 17624755 | VIRAL VECTOR THERAPY | January 2022 | February 2026 | Allow | 49 | 1 | 0 | No | No |
| 17617831 | RNA CONSTRUCT | December 2021 | October 2025 | Allow | 47 | 1 | 0 | No | No |
| 17545818 | MOLECULAR DETECTION OF NOVEL CORONAVIRUSES | December 2021 | December 2025 | Allow | 49 | 1 | 0 | No | No |
| 17522150 | VIRUS-LIKE PARTICLES | November 2021 | November 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17441524 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | September 2021 | July 2025 | Allow | 46 | 1 | 1 | No | No |
| 17433416 | NOVEL FISH TOTIVIRUS | August 2021 | June 2025 | Allow | 46 | 0 | 0 | No | No |
| 17369405 | CANCER IMMUNOTHERAPY USING VIRUS PARTICLES AND IMMUNE CHECKPOINT THERAPY | July 2021 | July 2025 | Allow | 48 | 1 | 0 | No | No |
| 17299062 | RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USES | June 2021 | March 2026 | Allow | 57 | 1 | 0 | No | No |
| 16579025 | BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE | September 2019 | January 2020 | Allow | 4 | 0 | 0 | No | No |
| 16388266 | COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION | April 2019 | July 2019 | Allow | 3 | 0 | 0 | No | No |
| 16385438 | BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE | April 2019 | June 2019 | Allow | 2 | 0 | 0 | No | No |
| 16098303 | THERAPEUTIC HPV VACCINE COMBINATIONS | November 2018 | August 2019 | Allow | 9 | 0 | 0 | No | No |
| 16174253 | VACCINES AND METHODS FOR CREATING A VACCINE FOR INDUCING IMMUNITY TO ALL DENGUE VIRUS SEROTYPES | October 2018 | February 2020 | Allow | 15 | 1 | 1 | No | No |
| 16074501 | METHODS OF PRODUCING VIRUSES | August 2018 | July 2019 | Allow | 12 | 0 | 1 | No | No |
| 16068845 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | July 2018 | September 2019 | Allow | 14 | 1 | 0 | No | No |
| 16063040 | COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES | June 2018 | December 2019 | Allow | 18 | 1 | 1 | No | No |
| 15777441 | DRIED INFLUENZA VACCINE PREPARATION AND METHOD FOR PRODUCING DRIED INFLUENZA VACCINE PREPARATION | May 2018 | May 2020 | Allow | 24 | 2 | 1 | No | No |
| 15777396 | VACCINE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR MANUFACTURING VACCINE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | May 2018 | June 2020 | Allow | 25 | 2 | 1 | No | No |
| 15701352 | HEPATITIS B THERAPEUTIC VACCINES | September 2017 | July 2018 | Allow | 10 | 0 | 1 | No | No |
| 15671360 | Anti-Viral Azide Containing Compounds | August 2017 | September 2018 | Allow | 13 | 1 | 1 | No | No |
| 15548919 | HUMAN NEUTRALIZING ANTIBODIES BINDING TO INFLUENZA NEURAMINIDASE | August 2017 | August 2018 | Allow | 13 | 1 | 1 | Yes | No |
| 15494017 | Compositions and Methods for Increasing Immunogenicity of Glycoprotein Vaccines | April 2017 | September 2018 | Allow | 17 | 1 | 1 | No | No |
| 15507525 | BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL COMPOSITION FOR HUMORAL IMMUNITY | February 2017 | July 2019 | Allow | 28 | 2 | 1 | Yes | No |
| 15501271 | COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION | February 2017 | December 2018 | Allow | 23 | 1 | 1 | No | No |
| 15304019 | GENERALIZABLE ASSAY FOR VIRUS CAPSID ASSEMBLY | October 2016 | September 2018 | Allow | 23 | 2 | 1 | No | No |
| 15272650 | POROUS MEMBRANE-BINDING PEPTIDES | September 2016 | June 2017 | Allow | 9 | 0 | 1 | Yes | No |
| 15114298 | METHOD FOR THE VACCINATION AGAINST HIV | July 2016 | July 2018 | Allow | 24 | 1 | 1 | Yes | No |
| 15031329 | A NOVEL METHOD FOR THE PRODUCTION OF STABILE VACCINES | April 2016 | October 2019 | Allow | 42 | 2 | 1 | No | No |
| 15022049 | METHOD FOR PRODUCING ENVELOPED VIRUSES | March 2016 | July 2018 | Allow | 28 | 2 | 1 | No | No |
| 14829158 | ALKYLATED INFLUENZA VACCINES | August 2015 | July 2018 | Allow | 35 | 3 | 1 | Yes | No |
| 14765365 | CELL LINES FOR VIRUS PRODUCTION AND METHODS OF USE | August 2015 | December 2017 | Allow | 28 | 3 | 1 | Yes | No |
| 14651635 | HIV THERAPEUTICS AND METHODS OF MAKING AND USING SAME | June 2015 | May 2017 | Allow | 24 | 1 | 1 | No | No |
| 14420720 | PRIMER SET FOR DETECTING BOVINE LEUKEMIA VIRUS AND USE THEREOF | February 2015 | September 2017 | Allow | 31 | 3 | 1 | Yes | No |
| 14555288 | SELECTIVE BINDING OF BIOLOGICAL TARGETS TO SOLID PHASE UREIDES | November 2014 | December 2016 | Allow | 25 | 3 | 1 | Yes | No |
| 14382769 | USE OF CENTRIFUGATION-AIDED INFECTION TO INCREASE VIRUS TITER | September 2014 | June 2018 | Allow | 45 | 5 | 1 | No | No |
| 14166965 | VACCINE COMPOSITION | January 2014 | May 2018 | Allow | 52 | 4 | 1 | No | No |
| 14152448 | COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS | January 2014 | September 2017 | Allow | 44 | 4 | 1 | No | No |
| 14152782 | VACCINES FOR PROTECTION FROM AND TREATMENT OF ALZHEIMER'S DISEASE | January 2014 | May 2016 | Allow | 28 | 1 | 1 | Yes | No |
| 14131061 | REAGENT STORAGE ON A DROPLET ACTUATOR | January 2014 | November 2016 | Allow | 35 | 2 | 1 | Yes | No |
| 14106461 | METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES | December 2013 | June 2019 | Allow | 60 | 5 | 1 | No | No |
| 13399654 | MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES | February 2012 | September 2016 | Allow | 55 | 4 | 1 | No | No |
| 13345334 | Viral Diagnostics | January 2012 | July 2014 | Allow | 30 | 2 | 1 | Yes | No |
| 13142090 | Novel Porcine Circovirus Type 2B Isolate and Uses Thereof | November 2011 | December 2013 | Allow | 30 | 2 | 1 | No | No |
| 13272828 | CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME | October 2011 | December 2014 | Allow | 38 | 2 | 1 | Yes | No |
| 13079472 | Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity | April 2011 | October 2015 | Abandon | 54 | 6 | 1 | Yes | No |
| 12736079 | RECOMBINANT VACCINIA VIRUS HAVING HEPATITIS C VIRUS GENE | February 2011 | April 2014 | Allow | 43 | 4 | 1 | Yes | No |
| 12988341 | TAT DNA SEQUENCES, GENE CONSTRUCTS, VACCINE AND PROCESSES THEREOF | January 2011 | June 2016 | Allow | 60 | 5 | 1 | Yes | No |
| 12995889 | NOVEL ANTIVIRAL PEPTIDE AGAINST AVIAN INFLUENZA VIRUS H9N2 | December 2010 | August 2014 | Allow | 44 | 2 | 1 | Yes | No |
| 12795211 | CELL LINE STABLY EXPRESSING MUTATED ONCOPROTEIN E6 AND METHOD OF SCREENING ANTICANCER COMPOUND OF UTERINE CERVICAL CANCER USING THE SAME | June 2010 | May 2014 | Allow | 47 | 2 | 1 | Yes | Yes |
| 12600460 | SIGNALING PEPTIDES | November 2009 | December 2012 | Allow | 37 | 1 | 1 | Yes | No |
| 12595358 | NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS | October 2009 | April 2016 | Allow | 60 | 5 | 1 | Yes | Yes |
| 12246803 | FLU VIRUS HEMAGGLUTININ SPECIFIC MONOCLONAL ANTIBODIES | October 2008 | December 2014 | Allow | 60 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHESTNUT, BARRY A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHESTNUT, BARRY A works in Art Unit 1672 and has examined 51 patent applications in our dataset. With an allowance rate of 98.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner CHESTNUT, BARRY A's allowance rate of 98.0% places them in the 90% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHESTNUT, BARRY A receive 1.94 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CHESTNUT, BARRY A is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -4.8% benefit to allowance rate for applications examined by CHESTNUT, BARRY A. This interview benefit is in the 5% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 73.3% of cases where such amendments are filed. This entry rate is in the 93% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 142.9% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.9% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.